Ligand Pharmaceuticals | LGND - Ebitda

Stock Price
213.21
Daily Change
-5.77 -2.63%
Monthly
-4.49%
Yearly
103.95%
Q2 Forecast
208.92

Ligand Pharmaceuticals reported $66.78M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
Baxter International USD -447M 873M Dec/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Enviri Corporation USD 70.13M 4.29M Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Pacira USD 40.24M 1.53M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 42.8M 488K Mar/2026